Disruption of NMDAR–CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model

Joel M. Brittain,1 Rui Pan,2 Haitao You,3 Tatiana Brustovetsky,4 Nickolay Brustovetsky,1,4 Gerald W. Zamponi,3 Wei-Hua Lee1,5 and Rajesh Khanna1,4,*

1Paul and Carole Stark Neurosciences Research Institute; Indiana University School of Medicine; Indianapolis, IN USA; 2Department of Pediatrics; Tongji Hospital; Tongji Medical College, Huazhong University of Science and Technology; Wuhan, Hubei, China; 3Department of Physiology and Pharmacology; Hotchkiss Brain Institute; University of Calgary; Calgary, Canada; 4Departments of Pharmacology and Toxicology, and Pediatrics; Indiana University School of Medicine; Indianapolis, IN USA; 5Indiana Spinal Cord and Brain Injury Research Group; Indiana University School of Medicine, Indianapolis, IN USA; 6Sophia Therapeutics LLC; Indianapolis, IN USA

Keywords: N-methylD-aspartate receptor, CRMP-2, peptide, focal cerebral ischemia, MCAO model

Submitted: 11/30/11
Accepted: 12/01/11
http://dx.doi.org/10.4161/chan.18919

*Correspondence to: Rajesh Khanna; Email: khanna5@iupui.edu

Addendum to: Brittain JM, Chen L, Wilson SM, Brustovetsky T, Gao X, Ashpole NM, et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP-2), J Biol Chem 2011; 286:7776–82, PMID:21832084; http://dx.doi.org/10.1074/jbc.M111.254665

Introduction

Neuronal insults such as TBI and stroke lead to a pronounced increase in extracellular glutamate surrounding the insult focus.1,2 The increased glutamate triggers neuronal death via hyperactivation of NMDARs and is known as excitotoxicity. Based upon these findings, expansive efforts have been made to develop NMDAR antagonists to prevent death of neurons following an excitotoxic insult. While in vitro discoveries have been plentiful, the majority of clinical trials using these antagonists have failed to yield treatment options.3,4 We reasoned that an alternative approach that may be more therapeutically beneficial is to modulate, rather than completely block, NMDARs to reduce excitotoxicity. This led to the identification and characterization of a novel modulator of NMDARs, a 15 amino acid peptide (CBD3) derived from the...
CRMP-2 protein and demonstrated its usefulness in preventing glutamate toxicity following neuronal injury.12 CRMP-2, initially believed to be a regulator of neuronal plasticity, neurite growth and extension,11,14 has emerged as a modulator of presynaptic voltage-gated Ca2+ channels in our recent studies characterizing the interaction between CRMP-2 and CaV2.2 channels (CaV2.2).10,12 The CRMP-2 peptide CBD3 was identified as a disrupter of the CRMP-2-CaV2.2 interaction and resulted in reduced Ca2+ channel current density and CaV2.2 trafficking.13 Fusion of the CBD3 peptide to the transactivating transcriptional activator (TAT) from human immunodeficiency virus conferred cell penetrating ability to CBD3 resulting in in vivo suppression of evoked pain in rat models of acute inflammatory and neuropathic pain.13,17 Since TAT-CBD3 exhibited a favorable safety profile in rodents,13,14 and CRMPs have been linked to excitotoxicity,13,17 we asked if TAT-CBD3 could have beneficial effects against excitotoxicity. We found that TAT-CBD3 selectively reduced NMDAR surface expression in dendrites and attenuated Ca2+-influx without completely ablating NMDA/Glutamate responses, a strategy that could be especially useful for reducing the excitotoxic death of neurons without preventing the "normal" post-injury glutamate excitatory synaptic transmission—which are important for continued survival of glumenteric neurons.17 In this addendum, we sought to further extend the neuroprotective scope of TAT-CBD3 by testing its efficacy in another excitotoxic injury model and to explore the biochemical mechanism(s) by which TAT-CBD3 targets NMDARs.

Results and Discussion

Neuroprotection by TAT-CBD3 against focal cerebral ischemia in the rat middle cerebral artery occlusion (MCAO) model. TAT-CBD3 administered systemically within minutes of a moderate controlled cortical injury protected ~50% of the neurons in the granular cell layer within the hippocampus against TBI and protected against an excitotoxic stimulation in vitro at 30 min post-challenge, supporting the notion that TAT-CBD3 works in the early phase of neuronal death observed following excitotoxic insults.19 To extend these findings, we asked if TAT-CBD3 would be effective in a transient model of focal cerebral ischemia (i.e., MCAO) and whether neuroprotection could be observed at a time the regions on CaV2.2 and NMDARs are involved in neuronal injury. The MCAO model was used here as (1) cell death in this model is dependent on excessive NMDAR activation,21,22 (2) NMDAR antagonists have been shown to be neuroprotective in animal models of ischemia,23,24 and (3) CRMP-2 levels are upregulated in the MCAO stroke penumbra.25 To confirm our hypothesis that TAT-CBD3 is effective in the early phase of neuronal death following excitotoxic insults, we first injected TAT-CBD3 (20 mg/kg) intraperitoneally (i.p.) 1 h prior to occlusion (Fig. 1A). The animals then underwent occlusion followed by a 2 h reperfusion and were sacrificed 48 h later. Cortices were sectioned and stained with 1% 2,3 and 5-triphenyltetrazolium chloride (TTC) to label viable tissue.26 TAT-CBD3 prior to MCAO caused an ~20% increase in surviving MCAO animals (Fig. 1B and C). This finding is consistent with our previous report showing TAT-CBD3 reduces neuronal death if given immediately following TBI as well as with a recent report that demonstrated a reduction in brain infarct volume following intracerebroventricular injection of a CRMP-2 peptide, partially overlapping (i.e., 6 of 15 amino acids) with our CBD3 peptide, in mice just before MCAO.27 To determine if TAT-CBD3 is effective if given hours after the occlusion, important since most stroke patients receive therapeutic intervention between a 3–8 h window, the peptide was injected i.p. 2 h after the onset of occlusion but 15 min prior to reperfusion. Two days after this procedure, the animals were sacrificed and cortices stained with TTC as above. A smaller (~10%) but significant sparing of surviving brain was observed in this paradigm compared with saline-injected animals (Fig. 1D and E). Collectively, these findings demonstrate that TAT-CBD3 acts as a neuroprotective agent both immediately and at least 2 h following an ischemic insult to the CNS.

Mechanistically, we have demonstrated that TAT-CBD3-mediated neuronal preservation in the face of an excitotoxic challenge likely occurs via attenuation of NMDAR-mediated Ca2+ influx. TAT-CBD3 slowed the onset of sustained time after the onset of injury. The MCAO model was used here as (1) cell death in this model is dependent on excessive NMDAR activation and, consequently, decelerated mitochondrial depolarization (Fig. 2). Thus, TAT-CBD3 alleviated glutamate-induced Ca2+-dysregulation and protected mitochondria against Ca2+-dependent injury. These findings are entirely consistent with neuroprotection conferred by NMDAR antagonists in animal models of ischemia.23 One caveat however, is that as neuroprotection is also observed following treatment with CaV2.2 antagonists in animal models of stroke and TBI,28,29 the role of CaV2.2 block in neuroprotection in these models cannot be completely ruled out given our previous demonstration of TAT-CBD3-mediated reduction in Ca2+ influx via these channels. That NMDARs are involved is unequivocal, however the role of CaV2.2 as it relates to TAT-CBD3-mediated neuroprotection is unclear. CaV2.2 blockers work to reduce extracellular glutamate and subsequently lead to reduced activation of NMDARs. Thus, neuroprotection with TAT-CBD3 in vivo likely results from a summed action on both NMDARs and CaV2.2. While there are obvious benefits of polypharmacology of action of TAT-CBD3 on two targets, ongoing mutagenesis efforts in our laboratory are geared toward the development of peptide(s) that may allow discrimination of CaV2.2 or NMDARs. It is still possible that the mechanism for antagonism of CaV2.2 and NMDARs may rely on the same motif within peptide(s) that may allow discrimination of CaV2.2 or NMDARs. It is still possible that the mechanism for antagonism of CaV2.2 and NMDARs may rely on the same motif within peptide(s) that may allow discrimination of CaV2.2 or NMDARs. A biochemical interaction between CRMP-2 and NR2B TAT-CBD3 targets NMDAR-mediated Ca2+ influx as well as reduces NMDAR currents within 5 min, although the exact mechanism for this antagonism is unknown.
The fast action of TAT-CBD3 may result from either a direct inhibition of the NMDAR or via a direct interaction with the NMDAR. To test the first possibility, we introduced TAT-CBD3 into neurons via the pipette and measured NMDAR currents. If TAT-CBD3 acts on the NMDAR exclusively at an extracellular site, then this method of peptide delivery is not expected to block currents. Conversely, if TAT-CBD3 acts on a NMDAR site intracellularly, inhibition of NMDAR currents would be observed.

We have previously shown that extracellular application of TAT-CBD3 is able to inhibit NMDAR Ca2+-currents. The mechanism of TAT-CBD3's inhibition of NMDARs was proposed to be due to intracellular disruption of CRMP-2-NMDAR signaling. This conclusion was supported by the finding that application of TAT-CBD3 but not CBD3 sans TAT was neuroprotective. While these findings supported the conclusion that the TAT penetration peptide is required for neuroprotection by CBD3 it did not directly demonstrate that the target of TAT-CBD3 was intracellular. Therefore, we tested if intracellular application of TAT-CBD3 inhibits NMDARs. This was tested by measuring NMDA-induced Ca2+-currents in hippocampal neurons with TAT-CBD3 in the recording pipette. In experiments where TAT-CBD3 was applied intracellularly via the recording pipette, there was no observed decrease in NMDAR Ca2+-currents compared with controls (Fig. 3). This finding suggests that TAT-CBD3 does not inhibit NMDARs through an intracellular target, suggesting instead that the observed inhibition of NMDARs by TAT-CBD3 may occur through an extracellular mechanism, such as channel block. This also suggests that the conformation per se of the fused version of the TAT with CBD3 bestows inhibition on the NMDARs, rather than other sequence alone. At present, however, it is unclear whether the previously observed internalization of NMDARs in response to TAT-CBD3 occurs through the proposed extracellular mechanism or through a distinct intracellular signaling target. Ongoing studies in our laboratory are investigating these scenarios.

A previous study has reported CRMP-2 as a biochemical binding partner of NMDAR NR2A/B subunits, and hence it is possible that the TAT peptide may mediate neuroprotection by disrupting the interaction between CRMP-2 and the NMDAR, rather than via current inhibition. To explore this interaction and determine if TAT-CBD3 affected it, we performed a series of co-immunoprecipitation experiments. Lysates from embryonic day 19 cortical neurons grown for 8 d in culture were exposed to TAT-CBD3 (100 μM) or TAT-control (100 μM) peptides or vehicle (1% DMSO) for 1 h and immunoprecipitated with an anti-NR2B antibody (recognizes proximal carboxyl-terminus, BD Biosciences) (Fig. 3A). Immunoblotting of these immunoprecipitates with a CRMP-2 antibody (recognizes amino acids 486-528, Immuno-Biological Laboratories) failed to yield a detectable interaction despite detection of PSD-95, a well-established interaction partner of NMDARs. Importantly, the interaction between PSD-95 and NR2B was not disrupted by...
TAT-CBD3, relevant here because disruption of this interaction has neuroprotective properties. The reciprocal co-immunoprecipitation with the anti-CRMP-2 (C4G) antibody on membrane enriched fractions from postnatal day 2 rat brains (Fig. 3B) also failed to pull down NR2B. It should be noted that the CRMP-2 antibody C4G was the same used in the previous study reporting an interaction between CRMP-2 and NMDARs. To rule out epitope specific or conformation specific NMDAR antibodies as the potential reasons for the lack of interaction in our cultures, we used two additional NR2B antibodies that have their epitopes in the N-terminus (NeuroMab) or in the C-terminus (Millipore) (Fig. 3C). These two also failed to resolve an interaction between NR2B and CRMP-2. To exclude the possibility that lysis and immunoprecipitation buffers were too stringent for maintenance of the interaction, a range of RIPA immunoprecipitation buffers were used in which the concentration of detergents (0.25–1% NP-40, 0.1% sodium dodecylsulfate, 0.5–1% sodium deoxycholate, 0.25% Triton X-100, or n-Octyl-Glucopyranoside) or salt (50 mM HEPES or 50 mM TRIS-HCl) were varied. None of these conditions, performed on embryonic or early postnatal day rat brains, synaptosomes or cultures yielded a positive interaction between CRMP-2 and NMDAR, whereas the interaction between NMDAR and PSD-95 was routinely observed.

Cross-linking agents formaldehyde, as well ortho- and para-isomers of phenylenediamine (PDM), which have different geometries and vary 2.5-fold in their cross-linking spans, were also used but failed to capture the NMDAR-CRMP-2 complex. Bacterially purified CRMP-2-GST fusion protein also failed to pull down NR2B from rat brain lysates or synaptosomes (Fig. 3D). Finally, we utilized a peptide array where we synthesized 15 amino acid peptides (overlapping by 12 amino acids) spanning the N-terminus (92 peptides), intracellular loop 1 (2 peptides), intracellular loop 2 (1 peptide), intracellular loop 3 (26 peptides) and C-terminus (106 peptides) of NR2B which was then overlaid with embryonic rat brain lysate for 1 h and probed in a far-Western simultaneously with a polyclonal CRMP-2 antibody and a monoclonal phospho-CRMP-2 (3F4) antibody that recognizes the cyclin dependent kinase 5 (cdk5) and glycogen synthase kinase 3β (GSK-3β) phosphorylation sites. Two peptides within the NMDAR C-terminus bound CRMP-2: peptide KPGMVFSISRGIYSC (residues 857–871 of the rat NR2B sequence) and DWED-RSGNNFCRSCP (residues 1205–1219 of the rat NR2B sequence) (Fig. 4). These peptides demonstrated relatively high (> 0.6 of normalized maximal) binding to both unphosphorylated and phosphorylated CRMP-2. The carboxyl-terminus of NR2 is believed to be inherently
unstructured\textsuperscript{39} and may “switch” between folded and unfolded states and this may explain the lack of an interaction between CRMP-2 and NR2B in our experiments. Following binding to adaptor proteins, the NR2B may embrace a tertiary confirmation that allows for binding of other proteins or peptides. In the peptide array here, while structural integrity is lost given the short lengths of the peptides, it is nevertheless possible that these “open” unstructured peptides facilitate binding to CRMP-2. While further work is necessary to definitively prove that these two peptides indeed bind CRMP-2 in other biochemical/biophysical experiments, it is perhaps not surprising that the carboxyl-terminus is the likely site of CRMP-2 interaction as this region is a proven nucleation point for NMDARs with demonstrated binding of $>75$ proteins including receptor, adaptor, signaling, cytoskeletal and novel proteins.\textsuperscript{40}

Conclusions. We have advanced the usefulness of TAT-CBD3 as a new therapeutic that may prove useful in managing chronic pain\textsuperscript{13,14} as it has been shown to alleviate inflammatory and neuropathic hypersensitivity by preventing CRMP2-mediated enhancements of Ca\textsubscript{V}2.2 function. We also demonstrated that TAT-CBD3 could mitigate neuronal death in the face of excitotoxic damage such as that resulting from a traumatic brain injury\textsuperscript{75} or focal cerebral ischemia. This latter effect involved block and/or internalization of NR2B. As it has been recently proposed that neurodegeneration/neuronal cell death may be an underlying cause of neuropathic pain,\textsuperscript{41} TAT-CBD3’s proven preservation of neurons and success at amelioration of neuropathic pain in rodent models puts it at the interface of these important and widespread medical problems. TAT-CBD3 may be a first-in-class therapeutic for treatment of neuroprotection as well as neuropathic pain.

Materials and Methods

All methods except those listed below were described by us previously.\textsuperscript{10,22} Materials and reagents. The antibodies (sources listed in parentheses) used were: whole mouse IgG (Jackson Immunoresearch), whole rabbit IgG (Jackson Immunoresearch), mouse anti-CRMP-2 C4G (Immuno-Biological Laboratories), rabbit anti-CRMP-2 (Sigma-Aldrich), mouse anti-NR2B (UC Davis/NIH).

Figure 4. CRMP-2 is not found in a complex with NR2B. The biochemical interaction between CRMP-2 and NR2B was investigated using in vitro binding assays. (A) Lysates from E19 DIV 8 cortical neurons were pre-incubated with vehicle (0.5% DMSO), TAT-Control (100 μM), or TAT-CBD3 (100 μM) prior to performing co-immunoprecipitations (IP w/) using an anti-NR2B antibody and immunoblotted for NR2B, PSD-95, and CRMP-2 as indicated. The commercial suppliers of the antibodies are indicated in parentheses. (B) Postnatal day 2 rat brain fractions were used to perform co-immunoprecipitations using anti-CRMP-2 C4G followed by western blot (WB) analyses. (C) Cortical neuron lysates were used to communoprecipitate NR2B using two additional NR2B antibodies and immunoblotted as in (A). (D) Bacterially expressed purified GST (control) or CRMP-2 GST proteins were utilized in pull downs (PD) from cortical neuron lysates along with either a monoclonal IgG (control) or CRMP-2 antibody, and then the immune-captured complexes were blotted with NR2B and CRMP-2 antibodies. Both GST-tagged and endogenous CRMP-2 are indicated. Molecular weight markers are indicated in kilodaltons (kDa).
Transient focal cerebral ischemia was observed in a human brain at term. Brain at this stage approximates that of 10-d-old Sprague-Dawley rats as the rat pups were weighed and anesthetized with 30% isoflurane in a mixture of 70% N\textsubscript{2}O and 30% O\textsubscript{2}. Following induction of anesthesia, 1.5% isoflurane was maintained and rectal temperature was monitored and maintained at 36–37°C with a heating blanket. With the animal supine, the left common carotid artery (CCA) were exposed. The external carotid artery (ECA) and internal carotid artery (ICA) were exposed. The left ECA was ligated. A noose was placed around the ICA to control backflow while the left CCA was ligated. A noose was placed on the CCA was loosened. Another noose was placed on the CCA to liberate IASP ethical guidelines. All rats had been blunted at the tip and coated with silicone, was introduced into the ECA lumen and gently advanced through the ICA up to the middle cerebral artery until a slight resistance was felt. The noose on the CCA was loosened. Similar procedures were performed on sham controls except that the suture was not advanced. After awakening, a brief behavioral assessment was performed on rats. The rats that were unable to exhibit circling to the right were regarded to have unsuccessful MCAO, and these animals were excluded from further study. Two hours later, the animals were re-anesthetized under the same conditions and the filament was removed to allow reperfusion.

NM2A current "rundown" assay in hippocampal neuron cultures. The methods for whole-cell voltage clamp recordings were described previously.\textsuperscript{28,42} For the NM2A current rundown assay, the pipette solution was supplemented with or without 10 μM TAT-CBD3. In both conditions, once the whole-cell configuration was achieved, a 30–40 sec period of time elapsed before collecting the first trace. For statistical evaluation of rundown, the peak currents were normalized to the current amplitude of first traces and expressed as means ± SEM.

**Figure 5.** Two NM2A carboxyl-terminus peptides bind to CRMP-2. Peptides (15-mers), with a moving window of three amino acids, were generated as intracellular regions of the rat NM2A. The SPOTS membranes were overlaid with rat brain lysates and then probed with polyclonal CRMP-2 and monoclonal phospho-CRMP-2 (3F4) antibodies. The intensity of each spot was measured using the Odyssey infrared imaging system utilizing the Li-Cor Biosciences one-dimensional software. Graphs represent normalized binding of poly (top) and mono (bottom) CRMP-2 antibodies to NM2A peptides. Peptides were defined to bind if binding with both antibodies was observed above an arbitrary threshold of 0.6 of maximum. Using these criteria, two carboxyl-terminal peptides bound CRMP-2. The sequences of these peptides are highlighted in boldface font.

30% isoflurane in a mixture of 70% N\textsubscript{2}O and 30% O\textsubscript{2}. Following induction of anesthesia, 1.5% isoflurane was maintained and rectal temperature was monitored and maintained at 36–37°C with a heating blanket. With the animal supine, the left common carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA) were exposed. The left ECA was ligated. A noose was placed around the ICA to control backflow while another noose was placed on the CCA to ischemic areas of (i.e., TTC-stained ipsilateral region) to ischemic areas of (i.e., TTC-stained contralateral region).

Culturing embryonic neurons. Cortical or hippocampal neurons were dissociated from embryonic day 19 rat and cultured as previously described.\textsuperscript{23} Calcium and mitochondrial membrane potential (ΔΨ) imaging. Neurons incubated in the growth medium were loaded at 37°C simultaneously with 2.6 μM Fura-2FF-AM (Molecular Probes) to follow changes in cytosolic Ca\textsuperscript{2+} and with 1.7 μM Rhodamine 123 (Molecular Probes) to monitor changes in mitochondrial membrane potential.\textsuperscript{54} During fluorescence recordings, neurons were incubated in the standard bath solution containing 139 mM NaCl, 3 mM KCl,
0.8 mM MgCl₂, 1.8 mM CaCl₂, 10 mM NaHEPES, pH 7.4, 5 mM glucose, and 45 mM sucrose: Fura-2FF and Rhodamine 123 fluorescence signals were followed with an inverted microscope Nikon Eclipse TE2000 using Nikon objective Super Fluor 20. 0.75 NA and a Photometrics CCD camera CoolSNAP HQ (Roper Scientific) controlled by MetaFluo software (Universal Imaging Corporation). The excitation light was delivered by a Lambda-LS system (Sutter Instruments). Fluorescence was recorded through a 505 nm dichroic mirror at 535 ± 25 nm. The changes in [Ca²⁺], were monitored by following F₃⁴₀/F₃₈₀, calculated after subtracting the background from both channels. The changes in [Ca²⁺] were monitored by following changes in fluorescence of Rhodamine 123 expressed as F₃₈₀/F₃₄₀. The Rhodamine 123 fluorescence traces were constructed after subtracting background fluorescence.

Cortical neuron lysates. Embryonic day 19 cortical neurons were grown for 10 d in culture before being washed in PBS (pH 8.0) and lysed in a modified RIPA buffer (1 mM EDTA, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, and freshly supplemented with protease inhibitors) by gentle rotation. Lysates were then clarified by centrifugation at 15,000 x g for 20 min at 4°C.

Coimmunoprecipitations and Immunoblotting. Coimmunoprecipitations were performed on freshly prepared or flash frozen lysates. For coimmunoprecipitations in the presence of TAT peptides, lysates were incubated with 100 µM TAT-Control or TAT-CBD or an equal volume of vehicle (DMSO) for 1 h at 37°C prior to addition of the primary antibody. Lysates were incubated with the primary antibody of interest under gentle agitation for 2 h or overnight at 4°C. Samples were then clarified to remove any additional precipitate and incubated with Protein A/G Plus for rabbit primary antibodies or Protein G Plus agarose for mouse primary antibodies (Santa Cruz Biotechnology) for 2 h at 4°C. The immune-captured complexes were then washed three times with lysate buffer before being boiled in equal volumes of SDS loading dye (Invitrogen). Samples were then processed by immunoblotting as previously described.10 Blots were probed with 1:1000 anti-NR2B (BD bioscience), 1:1000 anti-CRMP-2 (Sigma-Aldrich), or 1:1000 anti-PSD-95 (UC Davis/NIH NeuroMab Facility). All blots are representative of at least three experiments.

Preparation of postnatal day 2 (P2) rat brain membrane fractions were generated as previously described.10 Bacterial expression of CRMP-2 GST fusion protein. CRMP-2 GST was expressed in B. subtilis as previously described with minor modifications.9

References
1. Borromeo H, Druez J, Schwanke A, Dienel AH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by transcranial ultrasound. J Neurosci. 1986; 4(9):1309-16. PMID: 2846459; http://dx.doi.org/10.1136/jn.147.1.4159.198440539a
2. Faeder MJ, Donath P, Penny S, York R. The role of excitatory amino acids and NMDA receptors in inflammatory brain injury. Synapse 1989; 449-70889. PMID: 25075950; http://dx.doi.org/10.1111/j.1471-4159.2007.10476.x
3. Villetteau C, Becker CM. On the byps and falls in neuroprotection. Targeting the NMDA receptor. Neurosci Neurobiol. 2007; 134:9-15. PMID: 17191221; http://dx.doi.org/10.11177/j.1743842007.25345.25
4. Moor KW. Glimmer-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol. 2006; 6:570-578. PMID: 16859318; http://dx.doi.org/10.1016/j.coph.2005.12.002

5. Ogusayev KM, Rigaud AS, Stoffel S, Mehos TH, Forger F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomised placebos-controlled trial (MIDM 301). Stroke 2003; 34:88-89. PMID: 12519369; http://dx.doi.org/10.1161/01.STR.0000071951.05810.46
6. Reinhart B, Dodel R, Stoffel S, Schuett F, Forger S, Mehos TH. Memantine in moderate-to-severe Alzheimer’s disease, N Engl J Med. 2003; 348:1330-41. PMID: 12672860; http://dx.doi.org/10.1056/NEJMoa023118
7. Brittain JM, Chen L, Wilson SM, Brautweini T, Gao X, Arshad NM, et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein-2 (CRMP-2): J Red Cell 2011; 286:2778-82. PMID: 21382084; http://dx.doi.org/10.1074/jrc.110.97611.25745
8. Schmidt ER, Steinhauer MM, The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol. 2007; 608-11. PMID: 17607542; http://dx.doi.org/10.1007/978-0-387-74936-7_1

Acknowledgments
The authors would like to acknowledge Sarah Wilson, Dr My Khanna and colleagues at the Stark Neurosciences Research Institute (SNRI) for comments on the manuscript. The peptide blot was synthesized at the SNRI core facility by Dr Andy Hudmon with assistance from Nicolle Aspolke. This work was supported, in part, by grants from the Indiana Clinical and Translational Sciences Institute funded, in part by a Project Development Team Grant Number (RR025761) from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award, the Indiana State Department of Health—Spinal Cord and Brain Injury Fund (ATI-9-079138 to R.K.), the Indiana University Biomedical Sciences Award, the Indiana State Department of Health—Spinal Cord and Brain Injury Fund (ATI-9-079138 to R.K.), and the Elwert Award in Medicine to R.K. J. M.B. is the recipient of a Larry Kays Medical Neuroscience fellowship R.K. is a majority shareholder of Sophia Therapeutics I.L.C.
21. Kloda A, Martinac B, Adams DJ. Polymodal regulation

18. Bretin S, Rogemond V, Marin P, Maus M, Torrens Y,

17. Touma E, Kato S, Fukui K, Koike T. Calpain-

16. Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang

15. Hou ST, Jiang SX, Aylsworth A, Ferguson G, Slinn J,

13. Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard

dx.doi.org/10.1074/jbc.M111.255455

http://dx.doi.org/10.4161/chan.5.5.17363

34. Valentino K, Newcomb R, Gadbois T, Singh T, McCulloch J. The glutamate antagonist MK-801 inhibits NMDA receptor currents in cultured hippocampal neurons. J Neurosci 1995; 15:4133-44; PMID:7569905; http://dx.doi.org/10.1126/science.7569905

35. Kornau HC, Schenker LT, Kennedy MB, Seeburg PH. Antinociceptive efficacy of a mitoionic synapse inhibitor and a N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischemia. BR J PHARMAC 1994; 113:247-55; PMID:8279111

36. Golzowski GG, Nedergaard M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci 1996; 16:2157-63; PMID:8730786

30. Takahara A, Konda T, Enomoto A, Kondo N. Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model of NMDA receptor channelopathy. Channels (Austin) 2009; 3:66-72; PMID:19221512; http://dx.doi.org/10.1089/chan.5.5.17363

31. Lee LL, Gallo E, Ehlert RK, Münchau JP, Bernstein RF. Neuropeptide-F to the NMDA receptor in the isolated perfused rat thyroid gland. Endocr Res 1998; 24:495-505; PMID:9538902; http://dx.doi.org/10.1016/S0168-0102(98)00096-0

32. Perez-Pinzon MA, Yenari MA, Sun GH, Kunis DM, Dawson DA, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces the amount of surface NR2B NMDA receptor subunit. J Neurochem 2006; 98:1252-65; PMID:16688152; http://dx.doi.org/10.1016/j.neuroscience.2009.03.005

33. Bories P, Ranger S, Lévesque L, Pelletier S, Forestier F, Paré D, Truchon A. The glycine antagonist D-Tubocurarine reversibly inhibits sodium and calcium influx in the isolated rat atrium. BR J PHARMAC 1997; 150:457-55; PMID:9077076; http://dx.doi.org/10.1006/ajpl.1997.6662

34. Dumesnil DA, Graham CM, McNeill J, MacPherson IM. Antinociceptive efficacy of an N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischemia. BR J PHARMAC 1994; 113:247-55; PMID:8279111

35. Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang

24. Dawson MA, Furman EM, Jakes R, et al. Calpain-mediated NMDA receptor channelopathy in mice. Cell Calcium 2009; 46:18-29; PMID:19409612; http://dx.doi.org/10.1016/j.ceca.2008.07.003

23. Bordi F, Pietra C, Ziviani L, Reggiani A. The glycine antagonist D-Tubocurarine reversibly inhibits sodium and calcium influx in the isolated rat atrium. BR J PHARMAC 1997; 150:457-55; PMID:9077076; http://dx.doi.org/10.1006/ajpl.1997.6662

22. Piekarz RA, Pennock EK, Johnson JA, et al. Calpain-mediated NMDA receptor channelopathy in mice. Cell Calcium 2009; 46:18-29; PMID:19409612; http://dx.doi.org/10.1016/j.ceca.2008.07.003

21. Kloda A, Martinac B, Adams DJ. Polymodal regulation

18. Bretin S, Rogemond V, Marin P, Maus M, Torrens Y,

17. Touma E, Kato S, Fukui K, Koike T. Calpain-

16. Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang

15. Hou ST, Jiang SX, Aylsworth A, Ferguson G, Slinn J,

13. Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard

dx.doi.org/10.1074/jbc.M111.255455

http://dx.doi.org/10.4161/chan.5.5.17363

34. Valentino K, Newcomb R, Gadbois T, Singh T, McCulloch J. The glutamate antagonist MK-801 inhibits NMDA receptor currents in cultured hippocampal neurons. J Neurosci 1995; 15:4133-44; PMID:7569905; http://dx.doi.org/10.1126/science.7569905

35. Kornau HC, Schenker LT, Kennedy MB, Seeburg PH. Antinociceptive efficacy of a mitoionic synapse inhibitor and a N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischemia. BR J PHARMAC 1994; 113:247-55; PMID:8279111

36. Golzowski GG, Nedergaard M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci 1996; 16:2157-63; PMID:8730786

30. Takahara A, Konda T, Enomoto A, Kondo N. Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model of NMDA receptor channelopathy. Channels (Austin) 2009; 3:66-72; PMID:19221512; http://dx.doi.org/10.1089/chan.5.5.17363

31. Lee LL, Gallo E, Ehlert RK, Münchau JP, Bernstein RF. Neuropeptide-F to the NMDA receptor in the isolated perfused rat thyroid gland. Endocr Res 1998; 24:495-505; PMID:9538902; http://dx.doi.org/10.1016/S0168-0102(98)00096-0

32. Perez-Pinzon MA, Yenari MA, Sun GH, Kunis DM, Dawson DA, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces the amount of surface NR2B NMDA receptor subunit. J Neurochem 2006; 98:1252-65; PMID:16688152; http://dx.doi.org/10.1016/j.neuroscience.2009.03.005

33. Bories P, Ranger S, Lévesque L, Pelletier S, Forestier F, Paré D, Truchon A. The glycine antagonist D-Tubocurarine reversibly inhibits sodium and calcium influx in the isolated rat atrium. BR J PHARMAC 1997; 150:457-55; PMID:9077076; http://dx.doi.org/10.1006/ajpl.1997.6662

34. Dumesnil DA, Graham CM, McNeill J, MacPherson IM. Antinociceptive efficacy of an N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischemia. BR J PHARMAC 1994; 113:247-55; PMID:8279111

35. Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang

24. Dawson MA, Furman EM, Jakes R, et al. Calpain-mediated NMDA receptor channelopathy in mice. Cell Calcium 2009; 46:18-29; PMID:19409612; http://dx.doi.org/10.1016/j.ceca.2008.07.003